Investing.com - Entrada Therapeutics (NASDAQ: TRDA) reported first quarter EPS of $0.68, $1.42 better than the analyst estimate of $-0.74. Revenue for the quarter came in at $14.11M versus the consensus estimate of $11.22M.
Entrada Therapeutics's stock price closed at $13.50. It is down -10.77% in the last 3 months and up 19.07% in the last 12 months.
Entrada Therapeutics saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Entrada Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Entrada Therapeutics's Financial Health score is "great performance".
Check out Entrada Therapeutics's recent earnings performance, and Entrada Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar